Zhu Bin, Marinelli Brett A, Abbanat Darren, Foleno Barbara D, Bush Karen, Macielag Mark J
Research & Early Development, Johnson & Johnson Pharmaceutical Research & Development, L.L.C., 8 Clarke Drive, Cranbury, NJ 08512, USA.
Bioorg Med Chem Lett. 2007 Jul 15;17(14):3900-4. doi: 10.1016/j.bmcl.2007.04.104. Epub 2007 May 3.
A series of 3-keto-6-O-carbamoyl-11,12-cyclic thiocarbamate erythromycin A derivatives has been synthesized. The best compounds in this series possess potent in vitro antibacterial activity against erythromycin-susceptible and erythromycin-resistant bacteria.
已合成了一系列3-酮基-6-O-氨基甲酰基-11,12-环硫代氨基甲酸酯红霉素A衍生物。该系列中最佳的化合物对红霉素敏感菌和红霉素耐药菌具有强大的体外抗菌活性。